Hodgkin’s Lymphoma Treatment Market To Prove Its Servility To Technological Advancements

Lymphoma is a cancer caused in lymphocytes of the body, i.e. white blood cells. It is of two types — Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma. Hodgkin’s Lymphoma can be characterized into two categories — classic and nodular lymphocyte predominant. Some of the signs indicating presence of Hodgkin’s Lymphoma in the body is fever, sudden weight loss, and swollen lymph nodes. Hodgkin’s Lymphoma is mostly treated with chemotherapy alone or with the combination of radiotherapy.

• Hodgkin Lymphoma is a cancer of the lymphatic system known as lymphoma?a part of the immune system. This disease is mostly common in the age group of 20 to 40 years and above the age of 55 years. In Hodgkin lymphoma, cells in the lymphatic system grow abnormally and could spread further.
• Advancement in the diagnosis and treatment of Hodgkin lymphoma have driven complete recovery of the patient’s condition. Symptoms of Hodgkin lymphoma are swelling of lymph nodes, persistent fatigue, fever, night sweats, and weight loss.
• Main reason behind Hodgkin lymphoma is genetic mutation in the lymphoma, which drive the cells to multiply continuously. Mutation causes the lymphocyte cells to grow abnormally and enlarge to accumulate in the system. Classical Hodgkin Lymphoma is a common type of disease with diagnosis of large, abnormal cells known as Reed –Sternberg in the lymph nodes.
• Major site of the lymphoma tissue in the body are lymph nodes, lymph vessels, spleen, bone marrow, thymus, digestive tract, and adenoids & tonsils. Most common sites of Hodgkin Lymphoma are lymph nodes in upper body such as chest, neck, and under the arms.

North America is expected to hold a dominant position in the global Hodgkin’s lymphoma market over the forecast period. Frequent research and development activities done by the government and other organizations is expected to drive the North America Hodgkin’s lymphoma treatment market growth. For instance, in December 2016, Ohio State University Comprehensive Cancer Center and National Cancer Institute (NCI) commenced a U.S. FDA clinical trial of Ibrutinib in combination with Nivolumab, in the patients suffering from classical Hodgkin’s Lymphoma, in the U.S to study its efficacy. Ibritunib may block the cancer cell growth by blocking the enzymes responsible for growth and Nivolumab may block cancer cells by targeting different cells. Currently, it’s in the second phase of clinical trials. The study involves 17 participants and is estimated to be completed by 2020.